Related references
Note: Only part of the references are listed.ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
Audrey Carriere et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription
Matei Mireuta et al.
GROWTH FACTORS (2010)
Immunosuppressive Cyclosporin A Activates AKT in Keratinocytes through PTEN Suppression IMPLICATIONS IN SKIN CARCINOGENESIS
Weinong Han et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Altered VEGF mRNA Stability following Treatments with Immunosuppressive Agents IMPLICATIONS FOR CANCER DEVELOPMENT
Aninda Basu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation
Edward K. Geissler et al.
KIDNEY INTERNATIONAL (2010)
Advances in immunosuppression for renal transplantation
Antoine Durrbach et al.
NATURE REVIEWS NEPHROLOGY (2010)
Calcineurin Inhibitors Activate the Proto-Oncogene Ras and Promote Protumorigenic Signals in Renal Cancer Cells
Dipak Datta et al.
CANCER RESEARCH (2009)
Protein Kinase C-δ and Phosphatidylinositol 3-Kinase/Akt Activate Mammalian Target of Rapamycin to Modulate NF-κB Activation and Intercellular Adhesion Molecule-1 (ICAM-1) Expression in Endothelial Cells
Mohd Minhajuddin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors
Hiroshi Harada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Cyclosporin A Up-Regulates and Activates Protein Kinase C-ζ in EBV-Infected and EBV-Transformed Human B-Cells
Changguo Chen et al.
JOURNAL OF SURGICAL RESEARCH (2009)
The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy
Anthony P. Monaco
TRANSPLANTATION (2009)
Minimizing the Risk of Posttransplant Malignancy
Josep M. Campistol
TRANSPLANTATION (2009)
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer
Aninda Basu et al.
CANCER RESEARCH (2008)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PKC zeta-mTOR pathway: a new target for rituximab therapy in follicular lymphoma
Ludivine Leseux et al.
BLOOD (2008)
Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCε and PKCε in adult cardiac muscle cells
Phillip C. Moschella et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2007)
Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15183 recipients
A. C. Webster et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
The proline-rich akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1
Noriko Oshiro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding
Lifu Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Yasemin Sancak et al.
MOLECULAR CELL (2007)
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Emilie Vander Haar et al.
NATURE CELL BIOLOGY (2007)
Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin
Fan Pan et al.
NATURE (2007)
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich
C. D. Wimmer et al.
KIDNEY INTERNATIONAL (2007)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
mTOR, translational control and human disease
AR Tee et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation
M Guba et al.
TRANSPLANTATION (2004)
Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients
RT Bustami et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Malignancy in renal transplantation
C Morath et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Cancer after kidney transplantation in the United States
BL Kasiske et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice
GE Koehl et al.
TRANSPLANTATION (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways
CS Cho et al.
CELLULAR SIGNALLING (2003)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Signals transduced by Ca2+/calcineurin and NFATc3/c4 pattern the developing vasculature
IA Graef et al.
CELL (2001)
Recent advances in immunosuppressive therapy for renal transplantation
VR Peddi et al.
SEMINARS IN DIALYSIS (2001)
Role of protein kinase Cζ in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression
S Pal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Functional interaction between RAFT1/FRAP/mTOR and protein kinase C delta in the regulation of cap-dependent initiation of translation
V Kumar et al.
EMBO JOURNAL (2000)
Share Paper
